DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for VEXAS syndrome — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleVEXAS syndrome maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for vexas syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
ubiquitin like modifier activating enzyme 1 (UBA1) — UBA1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet ampdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9MC5 · 3.29 Å · ligand ADENOSINE MONOPHOSPHATE (AMP). Experimental structure, not a prediction.
What the evidence adds up to
VEXAS syndrome is caused by somatic mutations in the UBA1 gene and primarily affects men over 50. No established treatment guidelines exist. Current therapeutic approaches are based on limited evidence and their effectiveness remains inconsistent. Mortality can be as high as 40 percent. The disease presents with systemic inflammation, hematologic abnormalities, and features of clonal hematopoiesis; nearly half of patients develop myelodysplastic syndromes.
Treatments evaluated include corticosteroids, immunosuppressants, JAK inhibitors, and azacitidine. Responses remain variable. Allogeneic hematopoietic stem cell transplantation is discussed as a potential curative approach, but no survival or response rates from controlled trials are reported in these reviews. The interaction between inflammation and clonal expansion defines disease progression, and the correlation between specific UBA1 mutations and disease severity is noted.
One review states that targeted therapies offer symptomatic control, but responses remain variable. The other review offers a critical evaluation of efficacy and addresses gaps in the literature, but provides no concrete numbers for response rates or survival. There is no standardised therapy.
What is still missing are prospective trials with sufficient sample sizes to establish treatment guidelines, genotype-driven stratification to match therapies to mutation subtypes, and optimised protocols for allogeneic transplantation that report long-term outcomes. Funding for such trials and for biomarker development is lacking.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Clinical Medicine · 2024 · 14 citations · open access
VEXAS Syndrome: A Comprehensive Review of Current Therapeutic Strategies and Emerging Treatments
AbstractVEXAS syndrome is a recently identified autoinflammatory disorder resulting from somatic mutations in the UBA1 gene, leading to a complex spectrum of severe inflammatory and hematologic manifestations. The absence of established treatment guidelines and the variability in clinical presentation make its management particularly challenging. Current therapeutic approaches are often based on limited evidence, and their effectiveness remains inconsistent. This review seeks to consolidate the existing knowledge on therapeutic strategies for VEXAS syndrome, offering a critical evaluation of their efficacy and addressing the gaps in the current literature. As the clinical recognition of VEXAS grows, there is an urgent need to explore more targeted, effective treatments that can address both the inflammatory and hematologic aspects of the disease. By providing a comprehensive analysis of the current therapeutic landscape, this review aims to guide clinicians and researchers toward developing more effective, long-term management strategies for this life-threatening condition.
Expert Review of Hematology · 2025 · 4 citations · open access
Clonal hematopoiesis meets an autoinflammatory disease: the new paradigm of VEXAS syndrome
AbstractINTRODUCTION: VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is an acquired autoinflammatory disorder caused by somatic mutations in the UBA1 gene. Predominantly affecting males over 50, the disease presents with systemic inflammation, hematologic abnormalities, and features of clonal hematopoiesis, with nearly half of patients developing myelodysplastic syndromes (MDS). The interaction between inflammation and clonal expansion defines disease progression, emphasizing the need for a comprehensive understanding of its pathogenesis and management. AREAS COVERED: This review discusses the clinical spectrum, genetic landscape, and pathogenic mechanisms of VEXAS syndrome. The correlation between UBA1 mutations and disease severity is explored, alongside the role of clonal hematopoiesis and inflammatory pathways. Current treatments, including corticosteroids, immunosuppressants, JAK inhibitors, and azacitidine, are evaluated for efficacy and limitations. The potential of allogeneic hematopoietic stem cell transplantation (allo-HSCT) as a curative approach is also addressed. Literature search was conducted from January 2020 to present using PubMed and Scopus databases to identify relevant studies. EXPERT OPINION: VEXAS syndrome reflects a complex interaction between autoinflammation and clonal hematopoiesis. While targeted therapies offer symptomatic control, responses remain variable. Future strategies should focus on genotype-driven, personalized treatments and optimizing allo-HSCT protocols to improve patient outcomes and offer disease-modifying potential.
[VEXAS syndrome - a chameleon of inflammatory syndromes].
AbstractINTRODUCTION: The VEXAS syndrome is a systemic autoinflammatory disease first described in 2020. It primarily affects older men and is caused by a somatic mutation in the UBA1 gene on the X chromosome, leading to dysfunction of the innate immune system. Symptoms include fever, weight loss, various hematological manifestations, and a broad spectrum of clinical symptoms, often including ocular manifestations. Diagnosis is based on the detection of the mutation. There is currently no standardized therapy, and mortality can be as high as 40 %.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
